H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation ...

Research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Corvus Pharmaceuticals in ...

Fintel reports that on January 2, 2025, HC Wainwright & Co. initiated coverage of Corvus Pharmaceuticals (NasdaqGM:CRVS) with ...

Corvus Energy announced that it has been selected as the supplier of Energy Storage Systems (ESS) for Statue City Cruises' ferries servicing the iconic Statue of Liberty and Ellis Island routes in New ...

H.C. Wainwright initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $11 price target Corvus is a clinical-stage ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has earned a consensus recommendation of “Buy” from the four ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals (CRVS – Research Report) ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients ...

Investing.com -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)股票最初下跌高达18%，但随后出现显著反转，在公布其用于治疗中度至重度特应性皮炎的soquelitinib的I期试验中期结果后上涨7%。这家临床阶段生物制药公司发布的数据显示了良好的安全性和有效性，表明该药物不仅对这种慢性皮肤病有潜力，对其他免疫疾病也有潜力。

Nukkleus Inc. NUKK gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...